Comparative Pharmacology
Head-to-head clinical analysis: CORTAN versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTAN versus HC 1.
CORTAN vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Unknown
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
2–4 hours (terminal); prolonged in renal impairment.
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid